Patient Gateway

RSS Feed

Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios

Targetable KRAS G12C Mutation Uncommon in Genitourinary Cancers

BridgeBio Oncology reports new data for KRAS cancer drug BBO-8520

New Xenografts Data Have Been Reported by Researchers at Jiangsu Province Academy of Traditional Chinese Medicine [Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib...

New Findings in Non-Small Cell Lung Cancer Described from JSS Science and Technology University (Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant...

New Findings from University of Granada in the Area of Anticancer Agents Reported (Development of mitochondria-targeted isoquinolinium derivatives with dual fluorescence and anticancer activity against...

Expanding First-Line NSCLC Options: GenFleet Therapeutics Announces GFH375, Oral KRAS G12D (ON/OFF) Inhibitor, Advances into a Phase II Study Evaluating Monotherapy and Combination Regimens with...

Genfleet Therapeutics-B (02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, exploring multiple therapeutic regimens including monotherapy, combination with EGFR monoclonal anti

Jacobio Pharma Reports Profit Turnaround in 2026 Interim Results, Continues to Build Its KRAS Franchise